Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUOC-01 in Inherited Metabolic Diseases
NCT02254863Phase 1Recruiting
- Sponsor
- Joanne Kurtzberg
- Start
- Sep 2014
- Primary completion
- Oct 2027
- Modality
- CAR-Macrophages
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DUOC-01 in Inherited metabolic disorder (IMD), sponsored by Joanne Kurtzberg. Primary endpoints: Infusional Toxicity at 24 hours and Neuro Toxicity at 1 month. Started Sep 2014; status: recruiting.
02
Drugs
DUOC-01
03
Conditions
Inherited metabolic disorder (IMD)
Beyond the preview
Go deeper on NCT02254863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254863.